|Bid||803.40 x 0|
|Ask||803.60 x 0|
|Day's range||802.70 - 811.80|
|52-week range||534.70 - 834.50|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||40.22|
|Forward dividend & yield||10.40 (1.39%)|
|Ex-dividend date||25 Mar 2022|
|1y target est||784.25|
Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.
Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).